SEOUL, May 24 (Reuters) – South Korean biosimilars maker
Samsung Bioepis Co Ltd said on Tuesday it has applied to the
U.S. Food and Drug Administration (FDA) for approval to sell its
version of…
The post Samsung Bioepis applies for approval to sell Remicade biosimilar in U.S. appeared first on NASDAQ.